Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MapLight Therapeutics, Inc. - Common Stock (NQ:MPLT)

12.18 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6
Open 12.18
Bid (Size) 11.00 (100)
Ask (Size) 12.50 (200)
Prev. Close 12.18
Today's Range 12.18 - 12.18
52wk Range 9.100 - 40.43
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top movers analysis one hour before the close of the markets on 2026-07-29: top gainers and losers in today's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
Via Chartmill

Performance

YTD
-27.4%
-27.4%
1 Month
-66.7%
-66.7%
3 Month
-59.5%
-59.5%
6 Month
-30.7%
-30.7%
1 Year
-33.6%
-33.6%

More News

Read More
Which stocks are moving on Monday? ↗
Via Chartmill
News headline image
Maplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint ↗
Via MarketBeat
Monday's session: top gainers and losers ↗
Via Chartmill
News headline image
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Monday. ↗
Via Chartmill
News headline image
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Announces Changes to Board of Directors
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
Via The Motley Fool
News headline image
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
Via The Motley Fool
News headline image
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? ↗
Via The Motley Fool
Topics Derivatives Regulatory Compliance
News headline image
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics to Participate in Upcoming Investor Conferences
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April ↗
Via The Motley Fool
Topics Derivatives Regulatory Compliance
News headline image
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics to Participate in Upcoming Investor Conferences
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis
From MapLight Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is MapLight Therapeutics, Inc. - Common Stock publicly traded?
Yes, MapLight Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does MapLight Therapeutics, Inc. - Common Stock trade on?
MapLight Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MapLight Therapeutics, Inc. - Common Stock?
The ticker symbol for MapLight Therapeutics, Inc. - Common Stock is MPLT on the Nasdaq Stock Market
What is the current price of MapLight Therapeutics, Inc. - Common Stock?
The current price of MapLight Therapeutics, Inc. - Common Stock is 12.18
When was MapLight Therapeutics, Inc. - Common Stock last traded?
The last trade of MapLight Therapeutics, Inc. - Common Stock was at 08/10/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.